Evidence-based prevention: Increasing the efficiency of HIV intervention trials

Journal of Infectious Diseases

Volumn 190, Issue 4, 2004, Pages 663-665

  Padian, Nancy S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; NEVIRAPINE;

CONDOM; EVIDENCE BASED MEDICINE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; SHORT SURVEY;

ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; HIV INFECTIONS; HUMANS; INTERVENTION STUDIES;

EID: 3943056749     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422607     Document Type: Short Survey

References (7)

1. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update: December 2003. Geneva: UNAIDS and WHO, 2003.
3. Stover J, Walker N, Garnett GP, et al. Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet 2002; 360:73-7.
4. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125:605-13.
5. Aral SO, Peterman TA. Do we know the effectiveness of behavioral interventions? Lancet 1998; 351(Suppl 3):33-6.
6. Fleming TR, Richardson BA. Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis 2004; 190:666-74 (in this issue).
7. Padian N. The design of prophylactic trials for HIV: commentary. Epidemiology 2003; 14:83-4.